ClinicalTrials.gov
public full text
Public Domain
A Belatacept Compassionate Use Study for Patients With a Kidney Transplant
To make belatacept available for recipients of a renal allograft who are currently intolerant to or have contraindications to CNIs and/or m-TOR inhibitors and are either: * unable to construct an adequate immunosuppression regimen due to nonrenal toxicity / contraindication (and withdrawing the causative agent would lead to renal graft loss) OR * at imminent risk of losing the allograft kidney due to nephrotoxicity and have no other options for renal replacement therapy
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Individual Patient Compassionate Use of Nirogacestat#875891
- Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant#909929
- Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation#201660
- SEC 8-K — NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) (0001213900-18-013071) · filed 2018-09-27#608466
- A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients#863439
Record · ID 863020
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive